Entrepreneur Briefs

Transgenic Sciences Is Metamorphosing Transgenic Sciences lnc.—a startup that is banking on a future where chickens lay eggs that contain pharmaceutical proteins, pigs grow up with more meat and less fat than-they do now, and mice produce beneficial human proteins in their milk—is undergoing a few transformations itself this month. Led by new CEO James Sherblom, formerly of Genzyme Corp., the firm aims to raise $5 million and augment its scientific staff as a result of the initial

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Transgenic Sciences lnc.—a startup that is banking on a future where chickens lay eggs that contain pharmaceutical proteins, pigs grow up with more meat and less fat than-they do now, and mice produce beneficial human proteins in their milk—is undergoing a few transformations itself this month. Led by new CEO James Sherblom, formerly of Genzyme Corp., the firm aims to raise $5 million and augment its scientific staff as a result of the initial public offering it expects to complete in the next few weeks. If all goes according, to plan, the Worcester, Mass. - based company will add about six molecular biologists to its current staff of four full-time and four part-time researchers. The two-year-old startup also hopes to expand the scope of its research beyond the cooperative research agreements it has involving transgenic species. (The transgenic chicken project is being conducted with Tufts’ School of Veterinary Medicine; the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies